Alkermes (company)

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

Retrieved on: 
Wednesday, November 15, 2023

DUBLIN, Ireland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) today launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Mural’s ordinary shares will begin trading on the Nasdaq Global Market tomorrow, November 16th, under the ticker symbol “MURA”.

Key Points: 
  • “Immunotherapies have made a tremendous impact on the treatment of cancers over the past decade,” said Caroline Loew, Ph.D., the Company’s chief executive officer.
  • We believe Mural Oncology can lead the future of immunotherapies for patients.
  • Our protein engineering expertise allows us to reimagine the development of pro-inflammatory cytokine-based therapeutics that could address the key limitations with current cancer immunotherapies.
  • Goodwin Procter LLP and Arthur Cox LLP are serving as legal counsel to Mural Oncology.

Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences

Retrieved on: 
Wednesday, November 8, 2023

REDWOOD CITY, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that it will participate at the following upcoming medical and investor conferences in November:

Key Points: 
  • REDWOOD CITY, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that it will participate at the following upcoming medical and investor conferences in November:
    Live webcasts of the Stifel, Evercore and Piper presentations will be available on the Events & News – Presentations page of the Company's Investor Relations website.
  • An archived replay of each presentation will be available on the Company's website for 30 days following the live broadcast.

Mural Oncology to Host Investor Webcast on October 17

Retrieved on: 
Tuesday, October 10, 2023

DUBLIN, Oct. 10, 2023  /PRNewswire/ -- Mural Oncology plc, the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans to establish in the fourth quarter of 2023 (Mural Oncology), will hold an investor webcast during which members of Mural Oncology's designated management team will provide an overview of the company, its pipeline and strategy. The event will be webcast live on Tuesday, Oct. 17, 2023, at 11:00 a.m. ET.

Key Points: 
  • ET —
    DUBLIN, Oct. 10, 2023 /PRNewswire/ -- Mural Oncology plc , the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans to establish in the fourth quarter of 2023 (Mural Oncology), will hold an investor webcast during which members of Mural Oncology's designated management team will provide an overview of the company, its pipeline and strategy.
  • The event will be webcast live on Tuesday, Oct. 17, 2023, at 11:00 a.m.
  • "We are excited for the opportunities ahead for Mural Oncology and look forward to sharing an in-depth overview of our late-stage clinical asset, nemvaleukin alfa, an investigational immunotherapy, as well our preclinical pipeline candidates," said Dr. Caroline Loew, Chief Executive Officer designate of Mural Oncology.
  • Dr. Loew will be joined by members of the Mural Oncology team for a presentation followed by a question-and-answer session.

Mural Oncology to Host Investor Webcast on October 17

Retrieved on: 
Tuesday, October 10, 2023

DUBLIN, Oct. 10, 2023 /PRNewswire/ -- Mural Oncology plc, the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans to establish in the fourth quarter of 2023 (Mural Oncology), will hold an investor webcast during which members of Mural Oncology's designated management team will provide an overview of the company, its pipeline and strategy. The event will be webcast live on Tuesday, Oct. 17, 2023, at 11:00 a.m. ET.

Key Points: 
  • ET —
    DUBLIN, Oct. 10, 2023 /PRNewswire/ -- Mural Oncology plc , the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans to establish in the fourth quarter of 2023 (Mural Oncology), will hold an investor webcast during which members of Mural Oncology's designated management team will provide an overview of the company, its pipeline and strategy.
  • The event will be webcast live on Tuesday, Oct. 17, 2023, at 11:00 a.m.
  • "We are excited for the opportunities ahead for Mural Oncology and look forward to sharing an in-depth overview of our late-stage clinical asset, nemvaleukin alfa, an investigational immunotherapy, as well our preclinical pipeline candidates," said Dr. Caroline Loew, Chief Executive Officer designate of Mural Oncology.
  • Dr. Loew will be joined by members of the Mural Oncology team for a presentation followed by a question-and-answer session.

Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger and “WITHHOLD” Incumbent Director Richard Gaynor

Retrieved on: 
Wednesday, June 28, 2023

Shareholder pressure, including from Sarissa, has only incrementally moved the company in the right direction the last few years.

Key Points: 
  • Shareholder pressure, including from Sarissa, has only incrementally moved the company in the right direction the last few years.
  • If shareholders are not added to the board, we fear that Pops will continue to run the company as he pleases and never address its fundamental issues.
  • The board steadfastly refuses to add our nominees, including Sarah Schlesinger, who the Nom-Gov committee at Alkermes previously acknowledged would be a qualified board candidate and who ISS recommended that shareholders vote “FOR”.
  • Shareholders face an important decision at the upcoming Alkermes annual shareholder meeting.

Independent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders’ Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board

Retrieved on: 
Thursday, June 22, 2023

Shareholders should ask themselves a simple question – why would a purportedly well-functioning company undertake such actions?

Key Points: 
  • Shareholders should ask themselves a simple question – why would a purportedly well-functioning company undertake such actions?
  • Like ISS, we believe it is important to add direct shareholder representation to the Alkermes board.
  • The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov .
  • The definitive proxy statement and other relevant documents filed by Sarissa Capital are also available at no charge at www.upgradealkermes.com or by directing a request to Sarissa Capital’s proxy solicitor, D.F.

Independent Proxy Advisory Firm ISS Concludes That Sarissa Capital Has Made a Compelling Case for Change to the Alkermes Board

Retrieved on: 
Tuesday, June 20, 2023

Sarissa Capital Management LP (“Sarissa”) today made the following announcement regarding the conclusion reached by independent proxy advisory firm ISS that Sarissa has made a compelling case for change to the board of directors of Alkermes plc (NASDAQ: ALKS):

Key Points: 
  • Sarissa Capital Management LP (“Sarissa”) today made the following announcement regarding the conclusion reached by independent proxy advisory firm ISS that Sarissa has made a compelling case for change to the board of directors of Alkermes plc (NASDAQ: ALKS):
    We are pleased that ISS recognizes the compelling case for change to the Alkermes board.
  • ISS also concludes that with the pending spin of its cancer business, the value of Alkermes’ incumbent director Richard Gaynor will be reduced and therefore he should be removed from the Alkermes board.
  • Fellow Alkermes shareholders face an important decision at our upcoming annual shareholder meeting.
  • Like ISS, we believe it is important to add direct shareholder representation to the Alkermes board.

Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes

Retrieved on: 
Tuesday, June 13, 2023

Sarissa Capital today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS):

Key Points: 
  • Sarissa Capital today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS):
    We are one of Alkermes’ largest, long-term shareholders, owning nearly $450 million of stock.
  • We believe Pops understands that shareholder representation on the board will likely result in greater accountability and oversight.
  • Moreover, they each understand that they work for the shareholders and will provide essential oversight of management and accountability to shareholders.
  • We urge our fellow Alkermes shareholders to vote the BLUE universal proxy card “FOR” all Sarissa Nominees to provide much needed oversight and accountability at Alkermes.

Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders

Retrieved on: 
Monday, June 5, 2023

Richard Pops has presided over tremendous shareholder value destruction since becoming CEO of Alkermes over thirty years ago.

Key Points: 
  • Richard Pops has presided over tremendous shareholder value destruction since becoming CEO of Alkermes over thirty years ago.
  • For too long, Alkermes has been run for the benefit of management and not for shareholders.
  • In addition to issues with poor governance, expense management and capital allocation, Alkermes is basically a patchwork of subscale businesses.
  • If you vote by internet or telephone, you will be required to provide the unique control number printed on your BLUE universal proxy card.

Alkermes Announces Recipients of 2022 Alkermes Inspiration Grants® Program

Retrieved on: 
Thursday, October 27, 2022

DUBLIN, Oct. 27, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the 2022 recipients of the Alkermes Inspiration Grants® program. Grants were awarded to nine nonprofit organizations working to address the needs of people living with alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and cancer. The selected programs also have a focus on addressing unmet needs in historically under-resourced or underrepresented communities with longstanding and widespread health disparities.

Key Points: 
  • 6th Installment of Competitive Grants Program Awards Funding to Nine Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Cancer
    DUBLIN, Oct. 27, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the 2022 recipients of the Alkermes Inspiration Grants program.
  • "This year's Alkermes Inspiration Grants recipients inspire us with their innovative approaches to providing critical support for people living with addiction, serious mental illness or cancer, as well as their caregivers and family members.
  • Since 2016, the Alkermes Inspiration Grants program has awarded more than $4.5 million in funding to innovative programs that support the needs of those impacted by serious diseases in our areas of focus.
  • For more information on the Alkermes Inspiration Grants program, please visit https://www.alkermes.com/responsibility .